Tetra Bio-Pharma Inc. (TBPMQ)
OTCMKTS
· Delayed Price · Currency is USD
0.0002
0.00 (0.00%)
Mar 6, 2026, 4:00 PM EST
Tetra Bio-Pharma Income Statement
Financials in millions CAD. Fiscal year is December - November.
Millions CAD. Fiscal year is Dec - Nov.
Fiscal Year | TTM | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | 2016 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Aug '22 Aug 31, 2022 | Nov '21 Nov 30, 2021 | Nov '20 Nov 30, 2020 | Nov '19 Nov 30, 2019 | Nov '18 Nov 30, 2018 | Nov '17 Nov 30, 2017 | 2016 - 2014 |
| Selling, General & Admin | 7.3 | 11.12 | 8.27 | 6.65 | 4.68 | 2.48 | Upgrade
|
| Research & Development | 4.77 | 11.94 | 11.65 | 6.2 | 5.96 | 2.06 | Upgrade
|
| Operating Expenses | 12.33 | 24.12 | 20.49 | 13.08 | 12.07 | 6.68 | Upgrade
|
| Operating Income | -12.33 | -24.12 | -20.49 | -13.08 | -12.07 | -6.68 | Upgrade
|
| Interest Expense | -0.5 | -1.9 | - | - | - | - | Upgrade
|
| Earnings From Equity Investments | -0.65 | -0.95 | -0.27 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | - | - | -0.02 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | - | - | 0 | Upgrade
|
| EBT Excluding Unusual Items | -13.47 | -26.96 | -20.76 | -13.08 | -12.07 | -6.7 | Upgrade
|
| Gain (Loss) on Sale of Investments | -1.56 | -1.24 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | 4.23 | - | Upgrade
|
| Asset Writedown | -23.98 | -23.98 | -0.4 | - | - | - | Upgrade
|
| Pretax Income | -39.02 | -52.18 | -21.15 | -13.08 | -7.84 | -6.7 | Upgrade
|
| Earnings From Continuing Operations | -39.02 | -52.18 | -21.15 | -13.08 | -7.84 | -6.7 | Upgrade
|
| Earnings From Discontinued Operations | - | - | -5.32 | -2.2 | -0.01 | - | Upgrade
|
| Net Income to Company | -39.02 | -52.18 | -26.48 | -15.28 | -7.85 | -6.7 | Upgrade
|
| Minority Interest in Earnings | - | - | - | - | 0.28 | 0.47 | Upgrade
|
| Net Income | -39.02 | -52.18 | -26.48 | -15.28 | -7.57 | -6.23 | Upgrade
|
| Net Income to Common | -39.02 | -52.18 | -26.48 | -15.28 | -7.57 | -6.23 | Upgrade
|
| Shares Outstanding (Basic) | 423 | 402 | 258 | 188 | 146 | 108 | Upgrade
|
| Shares Outstanding (Diluted) | 423 | 402 | 258 | 188 | 146 | 108 | Upgrade
|
| Shares Change (YoY) | 26.48% | 55.60% | 37.14% | 29.21% | 35.15% | 66.33% | Upgrade
|
| EPS (Basic) | -0.09 | -0.13 | -0.10 | -0.08 | -0.05 | -0.06 | Upgrade
|
| EPS (Diluted) | -0.09 | -0.13 | -0.10 | -0.08 | -0.05 | -0.06 | Upgrade
|
| Free Cash Flow | -8.2 | -25.61 | -19.88 | -17.6 | -9.51 | -3.89 | Upgrade
|
| Free Cash Flow Per Share | -0.02 | -0.06 | -0.08 | -0.09 | -0.07 | -0.04 | Upgrade
|
| EBITDA | -12.23 | -24 | -20.45 | -13.05 | -12.06 | -6.67 | Upgrade
|
| D&A For EBITDA | 0.1 | 0.11 | 0.03 | 0.03 | 0.01 | 0.01 | Upgrade
|
| EBIT | -12.33 | -24.12 | -20.49 | -13.08 | -12.07 | -6.68 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.